Jane Street Group, LLC Biocryst Pharmaceuticals Inc Transaction History

Jane Street Group, LLC

$88.2 Billion
Q2 2024

A detailed history of Jane Street Group, LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Jane Street Group, LLC holds 839,508 shares of BCRX stock, worth $7.08 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

839,508

Previous 1,116,678 24.82%

Holding current value

$7.08 Million

Previous $5.67 Million 8.53%

% of portfolio

0.01%

Previous 0.01%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$4.13 - $6.79 $1.14 Million - $1.88 Million	-277,170 Reduced 24.82%	839,508 $5.19 Million
Q1 2024 May 15, 2024	BUY	$4.89 - $7.65 $1.44 Million - $2.25 Million	293,738 Added 35.69%	1,116,678 $5.67 Million
Q4 2023 Feb 14, 2024	BUY	$4.98 - $6.77 $1.02 Million - $1.38 Million	204,334 Added 33.03%	822,940 $4.93 Million
Q3 2023 Nov 14, 2023	BUY	$6.71 - $7.92 $1.28 Million - $1.51 Million	190,826 Added 44.61%	618,606 $4.38 Million
Q2 2023 Aug 14, 2023	BUY	$6.96 - $8.81 $1.07 Million - $1.35 Million	153,255 Added 55.83%	427,780 $3.01 Million
Q1 2023 May 15, 2023	SELL	$7.94 - $11.84 $162,110 - $241,737	-20,417 Reduced 6.92%	274,525 $2.29 Million
Q4 2022 Feb 14, 2023	BUY	$10.5 - $14.2 $2.38 Million - $3.22 Million	227,003 Added 334.13%	294,942 $3.39 Million
Q3 2022 Nov 14, 2022	SELL	$10.79 - $14.81 $1.06 Million - $1.46 Million	-98,619 Reduced 59.21%	67,939 $856,000
Q2 2022 Aug 16, 2022	BUY	$7.89 - $17.88 $540,646 - $1.23 Million	68,523 Added 69.9%	166,558 $1.76 Million
Q1 2022 May 17, 2022	SELL	$11.56 - $19.76 $1.8 Million - $3.08 Million	-155,683 Reduced 61.36%	98,035 $1.59 Million
Q4 2021 Feb 15, 2022	BUY	$11.18 - $15.46 $335,813 - $464,372	30,037 Added 13.43%	253,718 $3.51 Million
Q3 2021 Nov 16, 2021	SELL	$14.21 - $17.65 $29,769 - $36,976	-2,095 Reduced 0.93%	223,681 $3.21 Million
Q2 2021 Aug 16, 2021	SELL	$9.5 - $17.24 $1.58 Million - $2.87 Million	-166,297 Reduced 42.41%	225,776 $3.57 Million
Q1 2021 May 18, 2021	BUY	$7.37 - $13.61 $1.2 Million - $2.21 Million	162,313 Added 70.64%	392,073 $3.99 Million
Q4 2020 Feb 17, 2021	BUY	$3.37 - $8.61 $468,874 - $1.2 Million	139,132 Added 153.52%	229,760 $1.71 Million
Q3 2020 Nov 17, 2020	BUY	$3.43 - $5.53 $157,495 - $253,921	45,917 Added 102.7%	90,628 $311,000
Q2 2020 Aug 17, 2020	SELL	$1.9 - $5.61 $5,705 - $16,846	-3,003 Reduced 6.29%	44,711 $213,000
Q1 2020 May 15, 2020	BUY	$1.6 - $4.11 $50,150 - $128,823	31,344 Added 191.47%	47,714 $95,000
Q4 2019 Feb 14, 2020	SELL	$1.59 - $3.45 $572 - $1,242	-360 Reduced 2.15%	16,370 $56,000
Q3 2019 Nov 14, 2019	SELL	$2.5 - $3.73 $3,852 - $5,747	-1,541 Reduced 8.43%	16,730 $48,000
Q2 2019 Aug 15, 2019	BUY	$2.91 - $9.15 $53,168 - $167,179	18,271 New	18,271 $69,000
Q1 2018 May 15, 2018	SELL	$4.35 - $5.82 $119,838 - $160,335	-27,549 Closed	0 $0
Q4 2017 Feb 15, 2018	BUY	$4.16 - $5.33 $114,603 - $146,836	27,549	27,549 $135,000

Others Institutions Holding BCRX

# of Institutions

257

Shares Held

173M

Call Options Held

397K

Put Options Held

444K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.57B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account

Jane Street Group, LLC Biocryst Pharmaceuticals Inc Transaction History